TMCnet2d
FDA Issues Complete Response Letter for Etripamil for PSVT
Milestone Pharmaceuticals had $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024.
Fierce Pharma2d
Manufacturing issues trip up Milestone's long-awaited FDA landmark
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
Yahoo Finance2d
FDA Issues Complete Response Letter for Etripamil for PSVT
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...
Milestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
Investing.com Australia2d
Milestone stock tumbles after FDA letter on etripamil
Milestone (WA: MMD )’s President and CEO, Joe Oliveto, expressed the company’s disappointment with the CRL but reaffirmed their commitment to CARDAMYST as a potential novel treatment for PSVT. The ...
Investing2d
FDA flags issues with Milestone’s new drug application
The drug is also under study for atrial fibrillation with rapid ventricular rate (AFib-RVR). As of December 31, 2024, Milestone Pharmaceuticals reported having $69.7 million in cash, cash equivalents, ...